AI Portfolio Summary
In 2026 Q1, JOHNSON & JOHNSON maintained a portfolio of 18 distinct positions. The most significant new addition to the portfolio was Rallybio Corporation, which now represents 0.21% of the total fund value. Conversely, JOHNSON & JOHNSON completely exited their position in Lyell Immunopharma, .
Total Positions
18
Quarter
2026 Q1
Top Holding
PTGX (39.6%)
Top 10 Concentration
99.0%
Turnover Rate
23.4%
Sector HHI
0.18
Items per page:
Showing 1-18 of 18
| Stock | History | Sector / Type | Port % | Prev % | Rank / Prev | Conviction | Change | % Change | Influence | Shares | Mkt Value | Avg Cost | Price Held | 1st Owned | Source | Source Date | Date Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
PTGX
Protagonist The...
|
Healthcare | 39.57% | 38.57% |
#1
Prev: #1
|
7.0 | no change | no change |
P
S
|
2,449,183 | $258,143,888 | 2021 Q3 | 13F Filing | 2026-03-31 | 2026-05-13 | |||
|
NBTX
Nanobiotix S.A.
|
Healthcare | 26.61% | 23.44% |
#2
Prev: #2
|
6.5 | no change | no change |
P
S
|
5,623,816 | $173,607,200 | 2023 Q3 | 13F Filing | 2026-03-31 | 2026-05-13 | |||
|
MGTX
MeiraGTx Holdin...
|
Healthcare | 8.82% | 9.52% |
#3
1
Prev: #4
|
5.5 | no change | no change |
P
S
|
6,641,064 | $57,511,614 | 2021 Q3 | 13F Filing | 2026-03-31 | 2026-05-13 | |||
|
RAPP
Rapport Therape...
|
Healthcare | 8.56% | 9.76% |
#4
1
Prev: #3
|
4.9 | no change | no change |
P
S
|
1,784,517 | $55,837,537 | 2024 Q2 | 13F Filing | 2026-03-31 | 2026-05-13 | |||
|
CVRX
CVRx, Inc.
|
Healthcare | 5.84% | 5.15% |
#5
Prev: #5
|
3.8 | no change | no change |
P
S
|
4,024,861 | $38,075,185 | 2021 Q3 | 13F Filing | 2026-03-31 | 2026-05-13 | |||
|
CTNM
Contineum Thera...
|
Healthcare | 3.96% | 4.08% |
#6
Prev: #6
|
2.6 | no change | no change |
P
S
|
1,979,173 | $25,847,999 | 2024 Q2 | 13F Filing | 2026-03-31 | 2026-05-13 | |||
|
LEGN
Legend Biotech ...
|
Healthcare | 2.26% | 3.19% |
#7
Prev: #7
|
1.9 | no change | no change |
P
S
|
814,586 | $14,735,861 | 2021 Q3 | 13F Filing | 2026-03-31 | 2026-05-13 | |||
|
XNCR
Xencor, Inc.
|
Healthcare | 1.38% | 2.06% |
#8
Prev: #8
|
1.6 | no change | no change |
P
S
|
748,062 | $9,021,628 | 2021 Q4 | 13F Filing | 2026-03-31 | 2026-05-13 | |||
|
PRCT
Procept BioRobo...
|
Healthcare | 1.37% | 2.03% |
#9
Prev: #9
|
1.5 | no change | no change |
P
S
|
357,939 | $8,952,054 | 2021 Q3 | 13F Filing | 2026-03-31 | 2026-05-13 | |||
|
FATE
Fate Therapeuti...
|
Healthcare | 0.62% | 0.60% |
#10
Prev: #10
|
1.2 | no change | no change |
P
S
|
3,379,064 | $4,054,877 | 2021 Q3 | 13F Filing | 2026-03-31 | 2026-05-13 | |||
|
NMRA
Neumora Therape...
|
Healthcare | 0.55% | 0.60% |
#11
Prev: #11
|
1.2 | no change | no change |
P
S
|
1,849,445 | $3,606,418 | 2023 Q3 | 13F Filing | 2026-03-31 | 2026-05-13 | |||
|
N/A
Rallybio Corpor...
|
—
|
Unknown | 0.21% | — |
#12
Prev: #—
|
3.6 | 152,901 | no change |
NEW
|
152,901 | $1,371,522 | — | 13F Filing | 2026-03-31 | 2026-05-13 | ||
|
VOR
Vor Biopharma, ...
|
Healthcare | 0.15% | 0.13% |
#13
1
Prev: #14
|
1.1 | no change | no change |
P
S
|
53,732 | $958,579 | 2021 Q3 | 13F Filing | 2026-03-31 | 2026-05-13 | |||
|
LAB
Standard BioToo...
|
Healthcare | 0.04% | 0.07% |
#14
2
Prev: #16
|
1.0 | no change | no change |
P
S
|
311,967 | $286,791 | 2024 Q1 | 13F Filing | 2026-03-31 | 2026-05-13 | |||
|
NNOX
Nano-X Imaging ...
|
Healthcare | 0.03% | 0.08% |
#15
Prev: #15
|
0.0 | -75,298 | -47.4% |
P
S
|
83,554 | $189,668 | 2021 Q4 | 13F Filing | 2026-03-31 | 2026-05-13 | |||
|
ACET
Adicet Bio, Inc...
|
Healthcare | 0.02% | 0.03% |
#16
1
Prev: #17
|
1.0 | no change | no change |
P
S
|
22,779 | $155,125 | 2021 Q3 | 13F Filing | 2026-03-31 | 2026-05-13 | |||
|
LYEL
Lyell Immunopha...
|
Healthcare | 0.00% | 0.23% |
Sold All 😨
(Was: #13) |
0.0 | -41,165 | -100.0% |
CLOSED
|
— | $— | 2024 Q4 | 13F Filing | 2026-03-31 | 2026-05-13 | |||
|
RLYB
Rallybio Corpor...
|
Healthcare | 0.00% | 0.45% |
Sold All 😨
(Was: #12) |
0.0 | -3,636,363 | -100.0% |
CLOSED
|
— | $— | 2024 Q2 | 13F Filing | 2026-03-31 | 2026-05-13 |
Showing 1-18 of 18 holdings